OBJECTIVES:
The aim of this retrospective study is to evaluate the adherence of type 2 diabetes (T2DM) patients starting drug treatment to the ADA guidelines on HbA1Ctesting and treatment modification and determine its impact on treatment outcomes. METHODS: Data was obtained from a large health care plan claims database between July-2008 to December-2011. Eligible patients were aged ≥18 years with ≥2 T2DM diagnoses (ICD-9CM codes 250.x0, 250.x2), and were drugnaïve for ≥6 months before the first antidiabetic drug (termed "index treatment") was required. Patient adherence to the HbA1C testing guideline was defined as an initial HbA1C test within 105 days of the index treatment and subsequent tests within 105 or 195 days of the previous test depending on the result (≥7 or <7%, respectively). Adherence to the drug modification guideline was defined as a change in treatment within 45 days of HbA1C ≥7%. Patient outcome after one year was evaluated using the HbA1Cvalues closest to 365 days after index treatment. RESULTS: Of the 14,164 patients who met the study criteria, 4,419(31.20%) met the testing criteria for drug modification (HbA1C ≥7%). Of these patients, 546(12.36%) met the recommended testing frequency, 934(21.14%) adhered to the drug modification guidelines, and 117(2.65%) met both guidelines. The odds ratio of a patient achieving the HbA1C target (<7%) who adhered to the testing guideline was 4.66 compared with a patient who did not meet the testing guideline. Furthermore, the odds ratio of a patient in this population achieving the HbA1C target was 4.95 when both guidelines were met, as compared with a patient who met neither guideline. CONCLUSIONS: Adherence to ADA guidelines on HbA1C testing frequency and therapy modification correlated with improved outcomes one year after initial drug treatment. OBJECTIVES: To evaluate the relationship between self-monitoring of blood glucose (SMBG) test strip utilization and medication intensification in Type 2 diabetes mellitus (T2DM). METHODS: A retrospective study of Marketscan data examined patients with T2DM with ≥2 prescription claims or a 90-day supply of at least one non-insulin antihyperglycemic (AH) agent during a 4-month baseline period between July 1, 2006 to December, 31, 2009. The first claim for an AH was the index date. Patients were classified by number and dosage of AH agents, and by their utilization of SMBG test strips during the baseline period. Utilization of AH agents and insulin was assessed during follow-up between months 6-12 postindex. Medication intensification included an increase between baseline and follow-up in the number of AH classes used, an increase in dose, or the addition of insulin. An analysis of medication intensification from baseline to follow-up between users and non-users of SMBG test strips at baseline was conducted using chi-square analysis. RESULTS: Among 824,461 patients selected, 482,854 used one, 258,477 used two, and 83,130 used three AH agents at baseline. SMBG test strip use was observed in 28.3% of the entire population, with 17.0% using >4 test strips weekly. The following treatment changes occurred from baseline to follow-up: no change 67.9%, a decrease in AH classes 13.0%, an increase in AH classes 15.4%, initiating insulin 2.5%, and increasing dose 6.8%. The utilization of SMBG test strips at baseline in patients with no change or a decrease in medication intensification during follow-up was 28.0%, which was significantly different compared to SMBG use in patients with an increase in AH classes (29.1%), patients initiating insulin (32.8%), and in patients increasing dose (30.6%) (all P<0.001). CONCLUSIONS: The use of SMBG test strips is associated with medication intensification among users of AH therapy in T2DM. 
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PDB106 UTILIZATION TRENDS OF VARIOUS FORMULATIONS OF TESTOSTERONE: AN ANALYSIS OF THE RAMQ DATABASE
OBJECTIVES:
Testosterone is mainly used as androgen replacement therapy. The purpose of this study was to describe utilization trends of various testosterone formulations in a real life setting, using the RAMQ database. METHODS: Male patients covered by the Quebec provincial drug reimbursement program (RAMQ) who had used at least one formulation of testosterone in the period from June 1, 2003 to March 31, 2011 were selected. Characteristics of the treatments were analyzed, including switches from one formulation to another. A 1:1 control group matched for age of patients not using any formulation of testosterone was created and incidence of co-morbidities in patients in the study group was compared to the control group. RESULTS: Among a random sample of 125,000 patients covered by the drug plan, 723 males used at least one formulation of testosterone (0.57%). The average age was 57.2 years (SD=14.4). A total of 7 different formulations of testosterone were used by these patients. The most frequent formulations used during the study period were Andriol ® (48.4%) and Androgel ® (41.4%). Testosterone formulations were mainly prescribed by GPs (73%), endocrinologists (11.9%) and urologists (7.5%). About 32% of patients used more than one formulation during the study period. Among patients who switched from one formulation to another, switching to Androgel was the most frequent trend. Average treatment persistence varied from 147 days with Testim ® to 674 days with Androgel. Prevalence of many co-morbidities was significantly higher amongst these patients compared to the control group. Comorbidities included mental disorders (63.2%), hyperlipidemia (63.8%), hypertension (51.2%), articulation pain (32.1%) back pain (31.4%), HIV (6.2%) and migraine (6.6%). CONCLUSIONS: Patients on androgen replacement therapy have significantly more co-morbidities than controls. A significant proportion of patients will switch to a different formulation of testosterone over time, Androgel being the most frequent choice.
SENSORY SYSTEMS DISORDERS -Clinical Outcomes Studies
PSS1 THERAPEUTIC TRIAL OF INTRALESIONAL INJECTION OF MYCOPHENOLATE MOFETIL IN PSORIASIS VULGARIS: CLINICAL, HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL EVALUATION
Ashoush NN British University in Egypt, Cairo, Egypt OBJECTIVES: Systemically administered mycophenolate mofetil (MMF) has a beneficial effect in psoriasis patients. The purpose of the current study was to investigate the efficacy and safety of intralesional MMF in ordinary psoriasis vulgaris and to find out the best regimen of treatment. METHODS: In hundred plaque psoriasis patients, response to different concentrations (3.125, 6.25, 12.5 and 25 mg/ml) of MMF have been objectively evaluated and compared to control (5% dextrose). Patients were divided into two groups, group (A): patients who were injected once every two weeks for six weeks and group (B): patients who were injected once every week for six weeks. Patients were followed up clinically, histopathologically, and immunohisto-chemically for CD3. RESULTS: Maximum response to MMF was achieved 8 weeks after initiation of therapy. There was significant reduction of erythema, thickness, scaliness (P≤0.01) but not surface area (P=0.152) compared to control. Histopathologically, there was significant reduction in scores of parakeratosis, acanthosis, dilatation of papillary vessels and density of dermal mononuclear infiltrate. Immunohistochemical semi-quantitative analysis revealed variable, but in general, obvious degree of reduction in the density of CD3+ cellular infiltrate (i.e. T-cells) at the eighth visit compared to the first visit in all specimens examined. No significant difference could be seen in the efficacy of different concentrations with different regimens. No systemic or local adverse effects were noted apart from mild and transient burning sensation especially with higher concentrations. CONCLUSIONS: Intralesional MMF could be adopted as a safe and effective adjunctive line of treatment especially in localized plaque psoriasis.
